Leriglitazone

Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases[1][2][3][4].

Product Specifications

CAS Number

[146062-44-4]

Product Name Alternative

MIN-102; Hydroxypioglitazone

UNSPSC

12352005

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/leriglitazone.html

Purity

99.23

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=C(N1)SC(CC2=CC=C(OCCC3=NC=C(C(O)C)C=C3)C=C2)C1=O

Molecular Formula

C19H20N2O4S

Molecular Weight

372.44

References & Citations

[1]Santambrogio P, et al PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes. Pharmaceutics. 2023 Jan 6;15 (1) :202.|[2]Rodríguez-Pascau L, et al. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia. Neurobiol Dis. 2021 Jan;148:105162.|[3]Musokhranova U, et al. Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome. J Transl Med. 2023 Oct 26;21 (1) :756.|[4]Pizcueta P, et al. Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. Int J Mol Sci. 2023 Feb 6;24 (4) :3201.